Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Guelph

$17,500.00

Characterizing microbial ecosystems from inflammatory bowel disease patients

FY 2013-14

Summary
The human intestine is densely colonized by a diverse and abundant population of microbes, termed the microbiota. Intestinal bacteria are known to influence the development of immunity, and normal gut function. Disturbance of the intestine can lead to imbalance in the abundance profiles of the microbes, and potentially even the loss of some species; this state of imbalance, although poorly defined as yet, is termed ‘dysbiosis’. The consequence of dysbiosis may be the concomitant and increasing prevalence of obesity, allergy, autoimmunity, and Inflammatory Bowel Disease (IBD). Overall, reduced diversity, increased temporal instability, and increased proportions of pro-inflammatory versus anti-inflammatory bacteria are recurrent findings in IBD patients. Although the presence of dysbiosis in IBD is recognized, the mechanisms by which healthy microbial communities promote homeostasis and prevent inflammation are unclear. I hypothesize that gut microbial dysbiosis in IBD is related to functional deficits in ecosystem output in comparison to healthy ecosystems. I propose to use in vitro methods to characterize the functional output of gut microbial communities of derived, IBD-associated gut microbial communities. Chemostat technology, such as the ‘Robogut’ system in the laboratory of Dr. Emma Allen-Vercoe, will allow the reproducible culture of these defined ecosystems, and close control and manipulation of the conditions under which they are grown. My proposal has two main objectives: 1) To isolate and characterize microbial ecosystems from IBD patients. Successful work was done in the Allen-Vercoe lab to separately derive gut microbial ecosystems from fecal samples taken from 2 healthy donors. These ecosystems have been validated in the Robogut system, where they were found to behave in a similar manner to the fecal communities from which they were derived. I propose to use these defined ecosystems as controls for my work, and to use the methods by which they were derived in order to derive a further 4 model ecosystems; 2 from separate Crohn’s Disease (CD) patients, and 2 from separate Ulcerative Colitis (UC) patients. I will be provided with fresh fecal samples from CD and UC patients through an existing collaboration with Dr. Elena Verdu (McMaster University). 2) To measure the functional output of derived microbial ecosystems both before and after experimental perturbation. I will utilize Robogut vessels to support each derived ecosystem, and will measure functional output of each ecosystem through measurement of released volatile organic compounds (VOCs) by gas chromatography-mass spectroscopy. During each run, resistant starch addition will be incorporated to stimulate the ecosystem, and following this period each ecosystem will be stressed through the addition of antibiotics, with VOC measurements being taken at strategic points. I will also measure compositional changes in community structure using 16S ribosomal RNA gene sequencing techniques. I expect to find the following: 1. Gut microbial ecosystems derived from patients with IBD will be significantly less functionally diverse than control, healthy communities; 2. IBD-derived communities will suffer more detrimental changes in community structure following antibiotic perturbation compared to controls; 3. IBD-derived communities will produce greater amounts of metabolites that are considered to negatively affect the health of the host, and lesser amounts of beneficial metabolites in comparison to controls; 4. Defined ecosystems that I will produce as part of this project will prove to be reproducible and representative models of their originating fecal ecosystems, and will prove to be invaluable resource to the IBD research community in the future.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
312027
Name
Oliphant Kaitlyn G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing microbial ecosystems from inflammatory bowel disease patients
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Associated Disease; Bioactive Molecular Functional Output; Crohn'S Disease; Dysbiosis; Gut Microbiota; Inflammatory Bowel Disease; Microbial Ecosystem; Robogut Chemostat; Ulcerative Colitis; Volatile Organic Compounds
Abstract
The human intestine is densely colonized by a diverse and abundant population of microbes, termed the microbiota. Intestinal bacteria are known to influence the development of immunity, and normal gut function. Disturbance of the intestine can lead to imbalance in the abundance profiles of the microbes, and potentially even the loss of some species; this state of imbalance, although poorly defined as yet, is termed ‘dysbiosis’. The consequence of dysbiosis may be the concomitant and increasing prevalence of obesity, allergy, autoimmunity, and Inflammatory Bowel Disease (IBD). Overall, reduced diversity, increased temporal instability, and increased proportions of pro-inflammatory versus anti-inflammatory bacteria are recurrent findings in IBD patients. Although the presence of dysbiosis in IBD is recognized, the mechanisms by which healthy microbial communities promote homeostasis and prevent inflammation are unclear. I hypothesize that gut microbial dysbiosis in IBD is related to functional deficits in ecosystem output in comparison to healthy ecosystems. I propose to use in vitro methods to characterize the functional output of gut microbial communities of derived, IBD-associated gut microbial communities. Chemostat technology, such as the ‘Robogut’ system in the laboratory of Dr. Emma Allen-Vercoe, will allow the reproducible culture of these defined ecosystems, and close control and manipulation of the conditions under which they are grown. My proposal has two main objectives: 1) To isolate and characterize microbial ecosystems from IBD patients. Successful work was done in the Allen-Vercoe lab to separately derive gut microbial ecosystems from fecal samples taken from 2 healthy donors. These ecosystems have been validated in the Robogut system, where they were found to behave in a similar manner to the fecal communities from which they were derived. I propose to use these defined ecosystems as controls for my work, and to use the methods by which they were derived in order to derive a further 4 model ecosystems; 2 from separate Crohn’s Disease (CD) patients, and 2 from separate Ulcerative Colitis (UC) patients. I will be provided with fresh fecal samples from CD and UC patients through an existing collaboration with Dr. Elena Verdu (McMaster University). 2) To measure the functional output of derived microbial ecosystems both before and after experimental perturbation. I will utilize Robogut vessels to support each derived ecosystem, and will measure functional output of each ecosystem through measurement of released volatile organic compounds (VOCs) by gas chromatography-mass spectroscopy. During each run, resistant starch addition will be incorporated to stimulate the ecosystem, and following this period each ecosystem will be stressed through the addition of antibiotics, with VOC measurements being taken at strategic points. I will also measure compositional changes in community structure using 16S ribosomal RNA gene sequencing techniques. I expect to find the following: 1. Gut microbial ecosystems derived from patients with IBD will be significantly less functionally diverse than control, healthy communities; 2. IBD-derived communities will suffer more detrimental changes in community structure following antibiotic perturbation compared to controls; 3. IBD-derived communities will produce greater amounts of metabolites that are considered to negatively affect the health of the host, and lesser amounts of beneficial metabolites in comparison to controls; 4. Defined ecosystems that I will produce as part of this project will prove to be reproducible and representative models of their originating fecal ecosystems, and will prove to be invaluable resource to the IBD research community in the future.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Oliphant, Kaitlyn G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~